Orexo is a fully integrated specialty pharmaceutical company
Opioid addiction is a treatable chronic disease
Developed 4 products approved worldwide
Embracing all aspects of opioid addiction
We will be recognized for the added value our products bring to patients and societies
Orexo’s share is listed on Nasdaq Stockholm Mid Cap and available as American Depository Receipts (ADRs) on OTCQX in the US.
Follow Orexo in social media
Regulatory information that Orexo is obliged to make public pursuant to the EU Market Abuse Regulation, Securities Market Act and the Financial Instruments Trading Act.